Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Systemic sclerosis (SSc) is a connective tissue disorder characterized by fibroblast activation and fibrosis of the skin and internal organs. Alterations in cell–integrin interaction are sufficient to initiate profibrotic processes. SSc fibroblasts express both αvβ3 and αvβ5 integrins and their activation induces myofibroblasts differentiation. The aim of the present study was to evaluate the effect of the anb3 and anb5 inhibitor, cilengitide, on the development of vascular and fibrotic changes in the chronic oxidant stress murine model of systemic sclerosis. SSc was induced in BALB/c mice by daily s.c. injections of HOCl for 6 weeks. Mice were randomized in three arms: HOCl alone (n=8), HOCl + Cilengitide (n=8), or Vehicle alone (n=8). Treatment with cilengitide 20 (mg/kg/i.p./day) was started 4 weeks after the first administration of HOCl and maintained throughout the remaining experimental period (2 weeks). Lung, skin, and heart fibrosis were evaluated by histology while kidney morphology by PAS staining. Collagen type I, focal adhesion kinase (FAK), and a-SMA were evaluated by immunostaining and p-FAK and TGF-β1 by Western blot and gene expression. Both cutaneous and pulmonary fibrosis induced by HOCl were attenuated by cilengitide treatment. Cilengitide administration reduced a-SMA, TGF-β1, and p-FAK expression and the increased deposition of fibrillar collagen in the heart and prevented glomeruli collapse in the kidneys. The inhibition of aνβ3 and aνβ5 integrin signaling prevented systemic fibrosis and renal vascular abnormalities in the reactive oxygen species model of SSc. Integrins aνβ3 and aνβ5 could prove useful as a therapeutic target in SSc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, Cilengitide, an avb3/b5 antagonist, blocks immune cell adhesion and migration,inhibiting TGF-b -dependent myofibroblast differentiation, significantly reducing inflammatory infiltration and collagen deposition in liver and lung fibrosis models (130, 131).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [130]
Citations
Cites
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Changes in causes of death in systemic sclerosis, 1972–2002
Steen, V. D., & Medsger, T. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066068 · Cited by 1,528
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Mechanisms of Mechanotransduction
Orr, A. W., Helmke, B. P., Blackman, B. R., & Schwartz, M. A. (2006) · Developmental Cell · doi:10.1016/j.devcel.2005.12.006 · Cited by 798
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities
Bhattacharyya, S., Wei, J., & Varga, J. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.149 · Cited by 381
Hinz, B. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0017-1 · Cited by 373
Cross Talk among TGF- Signaling Pathways, Integrins, and the Extracellular Matrix
Munger, J. S., & Sheppard, D. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005017 · Cited by 372
Mutations in Fibrillin-1 Cause Congenital Scleroderma: Stiff Skin Syndrome
Loeys, B. L., Gerber, E. E., Riegert-Johnson, D., Iqbal, S., Whiteman, P., McConnell, V., Chillakuri, C. R., Macaya, D., Coucke, P. J., De Paepe, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000488 · Cited by 243
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., & Hatley, R. J. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 540
Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis
Tai, Y., Woods, E. L., Dally, J., Kong, D., Steadman, R., Moseley, R., & Midgley, A. C. (2021) · Biomolecules · doi:10.3390/biom11081095 · Cited by 240
Type V Collagen in Scar Tissue Regulates the Size of Scar after Heart Injury
Yokota, T., McCourt, J., Ma, F., Ren, S., Li, S., Kim, T.-H., Kurmangaliyev, Y. Z., Nasiri, R., Ahadian, S., Nguyen, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.030 · Cited by 209
“We subjected Col5a1CKO to ischemic cardiac injury and injected cilengitide or vehicle at 20mg/kg daily (Bagnato et al., 2018) for 14 days starting from the day of injury (Figure 7G).”
MethodOral Cavity Squamous Cell Carcinoma: An Update of the Pharmacological Treatment
Bellantoni, M. I., Picciolo, G., Pirrotta, I., Irrera, N., Vaccaro, M., Vaccaro, F., Squadrito, F., & Pallio, G. (2023) · Biomedicines · doi:10.3390/biomedicines11041112 · Cited by 96
Self-citationPomi, F. L., Papa, V., Borgia, F., Vaccaro, M., Allegra, A., Cicero, N., & Gangemi, S. (2023) · Antioxidants · doi:10.3390/antiox12030680 · Cited by 111
“Additionally, in this connective tissue disorder, the high levels of ROS contribute to the development of fibrotic processes and closely correlate with the severity of skin fibrosis [95,96].”
BackgroundSelf-citationIntegrins as a drug target in liver fibrosis
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74
The Role of Fibrinolytic Regulators in Vascular Dysfunction of Systemic Sclerosis
Kanno, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030619 · Cited by 68
Li, R., & Frangogiannis, N. G. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.07.006 · Cited by 62
Mannino, F., Imbesi, C., Bitto, A., Minutoli, L., Squadrito, F., D’Angelo, T., Booz, C., Pallio, G., & Irrera, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114666 · Cited by 60
Self-citationYuan, J., Li, P., Pan, H., Li, Y., Xu, Q., Xu, T., Ji, X., Liu, Y., Yao, W., Han, L., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123717 · Cited by 53
Proinflammatory Cytokines in Chronic Respiratory Diseases and Their Management
Chavda, V., Bezbaruah, R., Ahmed, N., Alom, S., Bhattacharjee, B., Nalla, L., Rynjah, D., Gadanec, L. K., & Apostolopoulos, V. (2025) · Cells · doi:10.3390/cells14060400 · Cited by 50
“TGF-β α TGF-β The mechanism of fibrosis in the lungs is largely dependent on the activation of TGF-β by αV-containing integrins [63,85].”
The role of macrophage-derived TGF-β1 on SiO 2 -induced pulmonary fibrosis: A review
Zhang, Z., Tian, H.-T., Hu, L., & Xie, R. (2021) · Toxicology and Industrial Health · doi:10.1177/0748233721989896 · Cited by 51
“At least four kinds of integrins containing v-subunit ( Vb3, Vb5, Vb6, and Vb8) have been associated with pulmonary fibrosis (Anderson et al., 2016; Bagnato et al., 2018; Kitamura et al., 2011; Luzina et al., 2009).”
BackgroundPerrucci, G. L., Barbagallo, V., Corlianò, M., Tosi, D., Santoro, R., Nigro, P., Poggio, P., Bulfamante, G., Lombardi, F., & Pompilio, G. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1730-1 · Cited by 38
“Moreover, a recent study evaluated the effectiveness of cilengitide in regression of fibrosis on a murine model of systemic sclerosis, a largely known fibrotic systemic disease [42].”
BackgroundBon, H., Hales, P., Lumb, S., Holdsworth, G., Johnson, T. S., Qureshi, O. S., & Twomey, B. M. (2019) · The Nephron journals/Nephron journals · doi:10.1159/000499506 · Cited by 39
Cooperative signaling between integrins and growth factor receptors in fibrosis
Maldonado, H., & Hagood, J. S. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02026-2 · Cited by 37
Inhibition of TGFβ1 activation prevents radiation-induced lung fibrosis
Yi, M., Yuan, Y., Ma, L., Li, L., Qin, W., Wu, B., Zheng, B., Liao, X., Hu, G., & Liu, B. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1546 · Cited by 33
“Recent studies have reported that cutaneous and pulmonary fibrosis are inhibited in systemic sclerosis and Crohn’s disease-induced intestinal fibrosis 21,27 and to limit the profibrotic response in cardiac fibroblasts.”
BackgroundWnt Signaling Pathways: From Inflammation to Non-Melanoma Skin Cancers
Bartolomeo, L. D., Vaccaro, F., Irrera, N., Borgia, F., Pomi, F. L., Squadrito, F., & Vaccaro, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021575 · Cited by 42
“Preventing the accumulation of ROS in cultured SSc patient cells restored WIF-1 expression, thus avoiding collagen accumulation [27].”
BackgroundSelf-citationCell adhesion molecules in fibrotic diseases
Hu, Q., Saleem, K., Pandey, J., Charania, A. N., Zhou, Y., & He, C. (2023) · Biomedicines · doi:10.3390/biomedicines11071995 · Cited by 32
Zhu, L., Liu, L., Wang, A., Liu, J., Huang, X., & Zan, T. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.05.001 · Cited by 42
Li, Y., Zhou, H., Bi, R., Li, X., Zha, M., Yang, Y., Ni, J., Liew, W. H., Olivo, M., Yao, K., et al. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb02282b · Cited by 32
(2025) · doi:10.3389/fimmu.2025.1670213 · Cited by 29
Cai, J., Wang, J., Jiang, C., Ye, L., He, X., Huang, J., Sun, X. Y., Ren, Z., Lai, X., Qiu, Y., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.007 · Cited by 24
Qin, H., Wen, H., Gu, K., Hu, X., Yang, T., Yan, X., Ye, T., Huo, J.-L., & Hu, J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s185418 · Cited by 20
“The Smad complex translocates into the nucleus, where it binds to a specific cis-acting element in the regulatory region of the TGF-β1 target genes (eg, α-SMA).(37) In the present study, the”
BackgroundMannino, F., Imbesi, C., Irrera, N., Pallio, G., Squadrito, F., & Bitto, A. (2023) · BioFactors · doi:10.1002/biof.2008 · Cited by 22
Self-citationPotential Role of Innate Lymphoid Cells in the Pathogenesis and Treatment of Skin Diseases
Borgia, F., Pomi, F. L., Alessandrello, C., Vaccaro, M., & Gangemi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12083043 · Cited by 14
“In scleroderma, skin remodeling is mainly supported by the proliferation of fibroblasts with collagen deposition, resulting in skin thinning and in the loss of skin elasticity, which is typical of patients affected by this pathology [40].”
BackgroundSelf-citationWang, L., Kulthinee, S., Slate‐Romano, J., Zhao, T., Shanmugam, H., Dubielecka, P. M., Zhang, L. X., Qin, G., Zhuang, S., Chin, Y. E., et al. (2023) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2023.104869 · Cited by 14
“It has been shown that Cilengitide increases the deposition of fibrillar collagen in the myocardium, revealing that inhibition of integrin α v β 5 signaling mediates systemic fibrosis in systemic sclerosis (Bagnato et al., 2018).”
BackgroundChristensen, K. B., Ünsal, Ş., Ebbesen, M. F., Hemstra, L. E., Schlosser, A. G., Rosenstand, K., Hansen, P., Jensen, B. L., Bloksgaard, M., Simonsen, U., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22283 · Cited by 8
Arena, S., Ieni, A., Currò, M., Vaccaro, M., Fabrizio, D. D., Cassaro, F., Bonfiglio, R., Montalto, A. S., Tuccari, G., Alibrandi, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11071986 · Cited by 12
Self-citationSui, S., & Hou, Y. (2021) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2021.1955960 · Cited by 10
Su, L., Sun, Q., Li, Y., Álvarez, J. F., Tao, B., Zhang, G., Gu, Y., Hanudel, M. R., Espinoza, A., Zhang, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ads7714 · Cited by 12
Smooth muscle αv integrins regulate vascular fibrosis via CD109 downregulation of TGF-β signalling
Li, Z., Belozertseva, E., Parlakian, A., Bascetin, R., Louis, H., Kawamura, Y. I., Blanc, J., Gao-Li, J., Pinet, F., Lacy‐Hulbert, A., et al. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead010 · Cited by 9
“These data also contrast with a prior study in the kidney showing that dual inhibition of αvβ3 and αvβ5 integrins is required to attenuate renal fibrosis.(5) Our data argue for the involvement of αvβ3 alone in the media of conduit arteries, here shown in the aorta and carotid arteries.”
ResultIntegrin activating molecule-talin1 promotes skin fibrosis in systemic sclerosis
Xu, D., Yuan, X., Zhao, L., & Mu, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400819 · Cited by 8
Blunting Neuroinflammation by Targeting the Immunoproteasome with Novel Amide Derivatives
Imbesi, C., Ettari, R., Irrera, N., Zappalà, M., Pallio, G., Bitto, A., & Mannino, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310732 · Cited by 7
Self-citationZhang, M., Wu, X., Zhu, H., Fu, C., Yang, W., Jing, X. B., Liu, W., & Cheng, Y. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10853-y · Cited by 4
“Downregulation of ITGB8 expression significantly alleviates fibrosis in the liver, lungs, and kidneys (Bagnato et al. 2018; McCarty 2020).”
Bagheri, L., Javanbakht, M., Malekian, S., Ghahderijani, B. H., Taghipour, S., Tanha, F. D., Ranjkesh, M. H., Cegolon, L., & Zhao, S. G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177607 · Cited by 5
Su, H., Fan, X., Nie, C., Tang, X., Hu, J., Xu, K., Zhang, L., & Ma, D. (2026) · Biomolecules · doi:10.3390/biom16010072 · Cited by 6
Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis
Han, X., Wang, X., Huang, J., & Yang, J. Y. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152811 · Cited by 3
Farh, M. E.-A., Kim, S. Y., Park, S., Cui, R., Sohn, I., & Cho, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121626 · Cited by 3
Lei, L., Zhao, C., Gao, W., Liu, G., Liu, M. Y., Lv, G., Fan, Z., Cheng, Y., Li, J., Kong, F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72394-9 · Cited by 6
Rôle des intégrines dans la fibrose cardiaque
Delacroix, C., & Hulot, J. (2022) · médecine/sciences · doi:10.1051/medsci/2022055 · Cited by 2
The Potential of Twendee X® as a Safe Antioxidant Treatment for Systemic Sclerosis
You, F., Nicco, C., Harakawa, Y., Yoshikawa, T., & Inufusa, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053064 · Cited by 1
Zhu, Z., Li, M., Meng, Q., Chen, H., Tan, C., & Zhang, H. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152507 · Cited by 1
Applying dendrimer nanoprobes to the diagnosis and evaluation of kidney fibrosis
Li, X., & Xu, L. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2628240 · Cited by 1
Targeting the αv Integrins in Fibroproliferative Disease
Nanthakumar, C. B., Hatley, R. J. D., & Slack, R. J. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00037 · Cited by 1
Asano, Y., & Distler, J. H. W. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_19
Rega, S., Bouhuis, S., Fanotti, N., Casaburo, M., Vodret, S., Riccitelli, F., Celotto, F., Lambroia, L., Climent, M., Elia, L., et al. (2025) · medRxiv · doi:10.1101/2025.03.21.25324435
Drug development in systemic sclerosis: novel therapeutics to watch
Batani, V., Colic, J., Scaletti, C., Molteni, R., Luca, G. D. D., Bandini, G., Dagna, L., Annunziato, F., Matucci‐Cerinic, M., & Campochiaro, C. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2636654
“In preclinical models, integrin modulation prevented or reversed dermal fibrosis and autoimmunity by attenuating TGF-β–driven fibroblast activation [105,107].”
The inflammatory/fibrotic axis across organs: myelofibrosis as a model of reversibility
Greven, L., Fuchs, S. N. R., Gleitz, H. F. E., & Schneider, R. K. (2026) · JCI Insight · doi:10.1172/jci.insight.202062
“Inhibition of the matrix protein thrombospondin-1 or α v β 3 / α v β 5 integrins suppresses TGF-β 1/SMAD3 signaling, collagen production, and fibrosis in peritoneal, renal, and cardiac injury models (82–86).”
Metadata
- Authors
- Bagnato, G. L., Irrera, N., Pizzino, G., Santoro, D., Roberts, W. N., Bagnato, G., Pallio, G., Vaccaro, M., Squadrito, F., Saitta, A., Altavilla, D., & Bitto, A.
- Affiliations
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
- University of Messina (IT)
- University of Louisville (US)
- Corresponding author
- Bitto, Alessandra
- ORCID
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2018-01-19
- Volume
- 132
- Issue
- 2
- Pages
- 231-242
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2772987505
- Cited by
- 51
- References
- 42
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 14 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 3 · 2018: 2
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- systemic sclerosis, cilengitide, integrin αvβ3, integrin αvβ5, integrin blockade, fibrosis, pulmonary fibrosis, skin fibrosis, renal fibrosis, vascular anomalies, myofibroblast differentiation, focal adhesion kinase, TGF-β1, reactive oxygen species, oxidative stress, therapeutic target
- MeSH terms
- Animals, Arteries, Disease Models, Animal, Female, Fibrosis, Humans, Mice, Inbred BALB C, Pulmonary Fibrosis, Scleroderma, Systemic, Skin, Snake Venoms, Gene Expression, Receptors, Vitronectin, Integrin alphaVbeta3, Transforming Growth Factor beta1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.